An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.
Also called NCT02561078
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 420 participants
- Registry
-
NCT02561078
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT02561078. Randomized; no masking; primary purpose treatment. Start 2015-10-20 (actual); primary completion 2017-05-09 (actual). Results posted on 2020-05-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
- Acronym
- VIVID
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Human regular U-500 insulin (CSII)
- Intervention (Drug)
- Human regular U-500 insulin (MDI)
- Lead sponsor
- Eli Lilly and Company
- Collaborator
- Insulet Corporation
Record details
- Record id
cardio:ct-nct02561078- Content hash
d20983228bc8b8a798640b3ddadf340a28abfb61750a6262c9eebf17de85a1c3